Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | UGCG | Q16739 | 2/20 | 0.40 |
| ▸ | MC4R | P32245 | 7/20 | 0.39 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 4/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459502 | 1.00 | CYP3A4 (0.40) | CYP3A4UGCGMC4RCYP51A1DPP4 | |
| SCHEMBL5452262 | 0.93 | MC4R (0.43) | CYP3A4UGCGMC4RCYP51A1CCR1 | |
| SCHEMBL5452078 | 0.93 | MC4R (0.43) | CYP3A4UGCGMC4RCYP51A1CCR1 | |
| SCHEMBL5447663 | 0.92 | MC4R (0.44) | CYP3A4UGCGMC4RCYP51A1CCR1 | |
| SCHEMBL5447660 | 0.92 | MC4R (0.44) | CYP3A4UGCGMC4RCYP51A1CCR1 | |
| SCHEMBL5452839 | 0.91 | MC4R (0.45) | CYP3A4UGCGMC4RCYP51A1 | |
| SCHEMBL5451683 | 0.91 | MC4R (0.45) | CYP3A4UGCGMC4RCYP51A1 | |
| SCHEMBL5465381 | 0.91 | MC4R (0.45) | CYP3A4UGCGMC4RCYP51A1 | |
| SCHEMBL5453848 | 0.91 | MC4R (0.45) | CYP3A4UGCGMC4RCYP51A1 | |
| SCHEMBL5465387 | 0.91 | MC4R (0.45) | CYP3A4UGCGMC4RCYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MC4R, MC5R, TAAR5 | CYP3A4 872/4885UGCG 1596/4885MC4R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.